A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Daiichi Sankyo
Related studies linked through entity extraction aliases.
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments
- Status
- COMPLETED
- Phase
- N/A
Castrate Resistant Prostate Cancer Enhertu Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
- Status
- COMPLETED
- Phase
- N/A
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
- Status
- RECRUITING
- Phase
- PHASE3
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
- Status
- COMPLETED
- Phase
- N/A
Real-World Pharmacological Treatment Pattern of Neuropathic Pain in China
- Status
- COMPLETED
- Phase
- N/A
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)
- Status
- RECRUITING
- Phase
- PHASE4
HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada
- Status
- COMPLETED
- Phase
- N/A
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Status
- RECRUITING
- Phase
- PHASE3
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
- Status
- RECRUITING
- Phase
- PHASE2
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A